NK antibody therapy: KIR-ative intent

Blood

Volumn 114, Issue 13, 2009, Pages 2567-2568

  Shah, Nina ^a   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA C ANTIGEN; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 1 7F9; IMMUNOGLOBULIN G4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 70449591587     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230904     Document Type: Note

References (7)

1. Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.
2. Lanier LL.NKcell recognition. Annu Rev Immunol. 2005;23:225-274.
3. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activatingNKreceptors. Trends Immunol. 2005; 26(4):221-226.
4. Ljunggren HG, Karre K. In search of the 'missing self': MHCmolecules andNKcell recognition. Immunol Today. 1990;11(7):237-244.
5. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
6. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics. 2001;52(3-4):195-205.
7. Baron F, Petersdorf EW, Gooley T, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant. 2009;15(5): 580-588.